Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3334-3339

  Tenero, David ^a   Bowers, Gary ^a   Rodvold, Keith A ^b   Patel, Apurva ^a   Kurtinecz, Milena ^a   Dumont, Etienne ^a   Tomayko, John ^a   Patel, Parul ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 2251052;

AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CONTACT DERMATITIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FLU LIKE SYNDROME; HICCUP; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MAXIMUM PLASMA CONCENTRATION; OROPHARYNX PAIN; ORTHOSTATIC HYPOTENSION; PHARMACOKINETICS; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; THORAX PAIN; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BORON COMPOUNDS; BRONCHOALVEOLAR LAVAGE; BRONCHOSCOPY; FEMALE; HALF-LIFE; HUMANS; LUNG; MACROPHAGES; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84879025639     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02483-12     Document Type: Article

References (14)

1. Hernandez V, Akama T, Alley M, Baker S, Mao W, Rock F, Zhang YK, Zhang Y, Zhou Y, Crepin T, Cusack S, Palencia A, Nieman J, Anugula M, Baek M, Diaper C, Ha C, Kermane M, Lu X, Mohammad R, Savariraj K, Sharma R, Singh R, Subedi R, Plattner J. 2010. Discovery and mechanism of action of AN3365: a novel boron-containing antibacterial agent in clinical development for Gram-negative infections, abstr F1-1637. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Mendes RE, Alley MRK, Sader HS, Biedenbach DJ, Jones RN. 2013. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli. Antimicrob. Agents Chemother. 57:2849-2857.
3. Mendez RE, Biedenbach DJ, Alley MRK, Sader HS, Jones RN. 2011. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against Enterobacteriaceae, abstr F1-1638. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Zane LT, Shakib S, Milne R, Liu L, Baker S, Heerinckx FA. 2011. Safety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052, in healthy subjects. Clin. Microbiol. Infect. 17(Suppl s4):s434.
5. Bulik CC, Okusanya OO, Bhavnani SM, Lepak A, Forrest A, Ambrose PG, Hoover JL, Andes DR. 2012. Evaluation of the pharmacokineticspharmacodynamics of GSK2251052 against gram-negative bacilli in a murine-thigh infection model, abstr A-1270. Proc. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. Andes DR, Okusanya OO, Bulik CC, Lepak A, Bhavnani SM, Forrest A, Hoover JL, Ambrose PG. 2012. Evaluation of the pharmacokineticspharmacodynamics of GSK2251052 against gram-negative bacilli using data from a neutropenic murine-pneumonia infection model, abstr A-1271. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
7. Hoover J, Mininger C, Rittenhouse S. 2012. GSK2251052, a novel LeuRS inhibitor, is effective against multi-drug resistant Pseudomonas aeruginosa in a mouse pneumonia model, abstr B-1308. Proc. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Craven DE. 2000. Epidemiology of ventilator-associated pneumonia. Chest 117(4 suppl 2):186S-187S. (Pubitemid 30230855)
9. U.S. Department of Health and Human Services. 2007. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. FDA, Rockville, MD. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceC omplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
10. Rodvold KA, Danziger LH, Gotfried MH. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47:2450-2457. (Pubitemid 36919444)
11. Nix DE. 1998. Intrapulmonary concentrations of antimicrobial agents. Infect. Dis. Clin. North Am. 12:631-645.
12. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538. (Pubitemid 16019939)
13. Tenero D, Patel P, Dumont E, Tomayko J. 2012. Development of a plasma/lung population pharmacokinetic (PPK) model for GSK2251052. Clin. Pharmacol. Drug Dev. 1:216. doi:10.1177/2160763X12454673.
14. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164. (Pubitemid 351269151)